Autres langues Clinuvel Pharmaceuticals Limited Nasdaq

Actions

CUVL

US1887691038

Produits pharmaceutiques

Temps réel estimé Cboe BZX 20:48:29 01/10/2026			Varia. 5j.	Varia. 1 janv.
5,700 ^USD	-4,36%		-2,04%	-33,23%

09/09	Clinuvel Pharmaceuticals Ltd achève le développement de Zerokin, un dispositif d'administration à usage unique pour les formulations à libération contrôlée	CI
08/09	Clinuvel Pharmaceuticals achève le développement de son dispositif exclusif d'administration de médicaments	MT

Autres langues

21/09	Clinuvel Pharmaceuticals Limited(ASX:CUV) added to S&P/ASX Emerging Companies Index
09/09	Clinuvel Pharmaceuticals Ltd Completes Development Of Zerokin Single-Use Administration Device For Controlled-Release Formulations
08/09	Clinuvel Pharmaceuticals Completes Development of Proprietary Drug Delivery Device
27/08	Clinuvel Pharmaceuticals Limited Declares Fully Franked Dividend for the Twelve Months Ended June 30, 2026, Payable on 18 September 2026
27/08	A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
27/08	Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2026
27/08	Clinuvel Board Mulls Change to Group Structure, Potential Nasdaq Listing, ASX Delisting; Shares Dive 9%
27/08	Clinuvel Pharmaceuticals Fiscal 2026 Earnings, Revenue Down
12/08	Clinuvel Pharmaceuticals Ltd Advances Controlled-Release Injectable Liquid Peptide Platform Vlrx-L and Selects First Candidates for Further Preclinical Studies
12/08	Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform
30/07	Clinuvel Pharmaceuticals Ltd Provides Commercial Update On Vitiligo And Reports Clinical Benchmarks For SCENESSE
30/07	Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market
28/07	Clinuvel Pharmaceuticals Ltd Provides Update On SCENESSE In Vitiligo
28/07	Clinuvel Pharmaceuticals Plans to Report Late-Stage Vitiligo Study Topline Results in December
23/07	Clinuvel Pharmaceuticals Limited to Reduce Global Workforce by Approximately 10%-20%
23/07	Clinuvel Pharmaceuticals Limited Announces Relocation of Corporate Headquarters to the United States
23/07	CLINUVEL implements strategic reorganisation to refocus on U.S. markets
23/07	Clinuvel Pharmaceuticals to Move Headquarters to US, Plan Workforce Reduction of Up to 20%
23/07	Australian Shares Open Higher as Oil, Gold Rally on Middle East Tensions; Santos Posts Higher Q2 Total Production
21/07	Clinuvel Pharmaceuticals Confirms ADS Start Trading on Nasdaq
21/07	Clinuvel Pharmaceuticals Limited(NasdaqGS:CUVL) added to NASDAQ Composite Index
20/07	CLINUVEL’s ADS to commence trading on Nasdaq
20/07	Clinuvel Pharmaceuticals' ADS to Begin Trading on Nasdaq
13/07	Clinuvel Pharmaceuticals Limited Receives Health Canada Notice of Compliance for Scenesse for Prevention of Phototoxicity in Adult Patients with Erythropoietic Protoporphyria
13/07	SCENESSE® approved for EPP in Canada